A5038094688- Synthesis and biological activity
- Organoselenium and organotellurium chemistry
- Cancer Treatment and Pharmacology
- RNA modifications and cancer
- Synthesis and Biological Evaluation
- Microbial Natural Products and Biosynthesis
- Molecular spectroscopy and chirality
- Metal complexes synthesis and properties
- Bioactive Compounds and Antitumor Agents
- Microtubule and mitosis dynamics
- Ferroptosis and cancer prognosis
- Receptor Mechanisms and Signaling
- Cancer therapeutics and mechanisms
- Hops Chemistry and Applications
- Quinazolinone synthesis and applications
- Click Chemistry and Applications
- Neurological Disorders and Treatments
- Genomics, phytochemicals, and oxidative stress
- Enzyme function and inhibition
- IL-33, ST2, and ILC Pathways
- Epigenetics and DNA Methylation
- 14-3-3 protein interactions
- Cancer, Lipids, and Metabolism
- Cholinesterase and Neurodegenerative Diseases
- Influenza Virus Research Studies
Guangzhou University of Chinese Medicine
2019-2025
Sun Yat-sen University
2014-2017
Two series of structurally related organoselenium compounds designed by fusing the anticancer agent methyl(phenyl)selane into tubulin polymerization inhibitors isocombretastatins or phenstatins were synthesized and evaluated for antiproliferative activity. Most these selenium containing hybrids exhibited potent cytotoxicity against a panel cancel cell lines, with IC50 values in submicromolar concentration range. Among them, 11a, 3-methylseleno derivative isocombretastatin A-4 (isoCA-4)...
ABSTRACT ZSP1273 is a novel small-molecule anti-influenza drug that targets the RNA polymerase PB2 subunit, while oseltamivir first-line medication inhibits neuraminidase. showed high efficacy against human influenza viruses both in vitro and vivo , including oseltamivir-resistant strains . In future clinical applications, combination of these two antiviral drugs with different mechanisms can reduce potential for resistance may arise from monotherapy. To evaluate drug–drug interaction...
Microtubule targeting agents (MTAs) are used as clinically effective chemotherapies for cancer treatment but might be limited by the acquired or intrinsic resistance of cells to apoptosis. The vulnerability therapy-resistant cancers ferroptosis provides an alternative way overcome drug resistance. In this study, on basis MTAs obtained in our previous studies, a series were synthesized, and detailed structure–activity relationships through extensive molecular dynamics studies. Among them,...
Oxidative stress is a major risk factor for neurodegenerative disease. The Kelch-like ECH-associated protein 1 (Keap1)–nuclear erythroid 2 related (Nrf2)–antioxidant response element (ARE) pathway one of the most potent defensive systems against oxidative stress. Selenepezil, selenium-based compound, was previously found to exhibit excellent acetylcholinesterase (AChE) inhibition, mimic endogenous glutathione peroxidase (GPx) activity, and scavenging activity hydrogen peroxide in vitro....
A series of novel chalcone analogues were designed, synthesized and evaluated as anticancer agents.
Cellular mesenchymal-epithelial transition factor (c-Met), an oncogenic transmembrane receptor tyrosine kinase (RTK), plays essential role in cell proliferation during embryo development and liver regeneration. Thioredoxin reductase (TrxR) is overexpressed constitutively active most tumors closely related to cancer recurrence. Multi-target-directed ligands (MTDLs) strategy provides a logical approach drug combinations would adequately address the pathological complexity of cancer. In this...
Our findings revealed the benzylideneindanone moiety as a new attractive scaffold for mitosis-targeting drug discovery.
In the search for novel antitumor agents, a series of cyclic<bold>CA-4</bold>analogues bearing amide group, A–B or B–C ring condensation, and CC CN bond in B were designed, synthesized identified as microtubule inhibitors.
Microtubules are attractive targets for anticancer drugs. However, the microtubule-targeting agents (MTAs) currently in clinical use exhibit inevitable drug resistance. Therefore, there is an urgent need to discover novel MTAs treatment of cancer.
Abstract Background: Fuzheng Kang-Ai decoction (FZKA), which consists of twelve Chinese herbal medicines (CHM), has been extensively used in the treatment Non-Small Cell Lung Cancer (NSCLC) patients. It was reported our preceding study that progression-free survival (PFS) could be prolonged and toxic effect reduced after combination FZKA Gefitinib (GFTN) comparing to GFTN alone. Recent studies have shown promote ferroptosis NSCLC cells. Hence, we assumed might strengthen by regulating cell...